These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 27196599)

  • 1. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
    Jiang YY; Lin DC; Mayakonda A; Hazawa M; Ding LW; Chien WW; Xu L; Chen Y; Xiao JF; Senapedis W; Baloglu E; Kanojia D; Shang L; Xu X; Yang H; Tyner JW; Wang MR; Koeffler HP
    Gut; 2017 Aug; 66(8):1358-1368. PubMed ID: 27196599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
    Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
    Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma.
    Yuan J; Jiang YY; Mayakonda A; Huang M; Ding LW; Lin H; Yu F; Lu Y; Loh TKS; Chow M; Savage S; Tyner JW; Lin DC; Koeffler HP
    Cancer Res; 2017 Dec; 77(23):6614-6626. PubMed ID: 28951465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
    Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
    Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
    [No Abstract]   [Full Text] [Related]  

  • 5. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
    Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
    Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
    Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.
    Zhang J; Liu W; Zou C; Zhao Z; Lai Y; Shi Z; Xie X; Huang G; Wang Y; Zhang X; Fan Z; Su Q; Yin J; Shen J
    Clin Cancer Res; 2020 Jun; 26(11):2681-2692. PubMed ID: 31937612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.
    Kwiatkowski N; Zhang T; Rahl PB; Abraham BJ; Reddy J; Ficarro SB; Dastur A; Amzallag A; Ramaswamy S; Tesar B; Jenkins CE; Hannett NM; McMillin D; Sanda T; Sim T; Kim ND; Look T; Mitsiades CS; Weng AP; Brown JR; Benes CH; Marto JA; Young RA; Gray NS
    Nature; 2014 Jul; 511(7511):616-20. PubMed ID: 25043025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
    Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X
    Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
    Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
    J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
    Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
    Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
    Chow PM; Chang YW; Kuo KL; Lin WC; Liu SH; Huang KH
    Cancer Lett; 2021 Jun; 507():70-79. PubMed ID: 33741425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
    Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
    Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
    Zhong L; Yang S; Jia Y; Lei K
    J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer.
    Zhang Z; Peng H; Wang X; Yin X; Ma P; Jing Y; Cai MC; Liu J; Zhang M; Zhang S; Shi K; Gao WQ; Di W; Zhuang G
    Mol Cancer Ther; 2017 Sep; 16(9):1739-1750. PubMed ID: 28572168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome.
    Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F
    Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes.
    Sampathi S; Acharya P; Zhao Y; Wang J; Stengel KR; Liu Q; Savona MR; Hiebert SW
    Nucleic Acids Res; 2019 May; 47(8):3921-3936. PubMed ID: 30805632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma.
    Eliades P; Abraham BJ; Ji Z; Miller DM; Christensen CL; Kwiatkowski N; Kumar R; Njauw CN; Taylor M; Miao B; Zhang T; Wong KK; Gray NS; Young RA; Tsao H
    J Invest Dermatol; 2018 Jul; 138(7):1582-1590. PubMed ID: 29408204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
    Huang CS; Xu QC; Dai C; Wang L; Tien YC; Li F; Su Q; Huang XT; Wu J; Zhao W; Yin XY
    ACS Nano; 2021 Sep; 15(9):14744-14755. PubMed ID: 34405985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
    Cheng ZJ; Miao DL; Su QY; Tang XL; Wang XL; Deng LB; Shi HD; Xin HB
    Acta Pharmacol Sin; 2019 Jun; 40(6):814-822. PubMed ID: 30446732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.